An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued
Jun 14
Chinese (SSE) Biotech Industry Analysis
UpdatedJun 14, 2024
DataAggregated Company Financials
Companies73
- 7D1.4%
- 3M-13.2%
- 1Y-18.7%
- YTD-19.7%
The Biotech industry has been flat over the last week, but Imeik Technology DevelopmentLtd has lost 5.8%. As for the longer term, the industry has declined 18% in the last year. As for the next few years, earnings are expected to grow by 32% per annum.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 14 Jun 2024 | CN¥891.4b | CN¥161.1b | CN¥17.3b | 33.3x | 51.5x | 5.5x |
| Sun, 12 May 2024 | CN¥979.5b | CN¥161.1b | CN¥17.3b | 38.3x | 56.8x | 6.1x |
| Tue, 09 Apr 2024 | CN¥940.4b | CN¥161.1b | CN¥20.2b | 38.5x | 46.6x | 5.8x |
| Thu, 07 Mar 2024 | CN¥1.0t | CN¥165.5b | CN¥22.1b | 35.3x | 45.3x | 6x |
| Sat, 03 Feb 2024 | CN¥849.7b | CN¥167.9b | CN¥21.4b | 30.4x | 39.7x | 5.1x |
| Mon, 01 Jan 2024 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 40.6x | 52.3x | 6.7x |
| Wed, 29 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.2x | 53.1x | 6.8x |
| Fri, 27 Oct 2023 | CN¥1.0t | CN¥170.6b | CN¥25.0b | 38.7x | 40.7x | 6x |
| Sun, 24 Sep 2023 | CN¥1.0t | CN¥170.9b | CN¥25.2b | 39.3x | 41.1x | 6.1x |
| Tue, 22 Aug 2023 | CN¥1.0t | CN¥173.7b | CN¥28.2b | 37x | 36.2x | 5.9x |
| Thu, 20 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.9b | 38.6x | 35.3x | 6x |
| Sat, 17 Jun 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 38.7x | 37.3x | 6.2x |
| Mon, 15 May 2023 | CN¥1.1t | CN¥177.8b | CN¥29.6b | 40.7x | 38.8x | 6.5x |
| Wed, 12 Apr 2023 | CN¥1.3t | CN¥186.0b | CN¥36.4b | 42.1x | 35.1x | 6.9x |
| Fri, 10 Mar 2023 | CN¥1.3t | CN¥179.0b | CN¥36.0b | 44.4x | 35.2x | 7.1x |
| Sun, 05 Feb 2023 | CN¥1.3t | CN¥179.6b | CN¥37.9b | 44.1x | 34.9x | 7.4x |
| Tue, 03 Jan 2023 | CN¥1.2t | CN¥175.6b | CN¥37.9b | 38.7x | 32x | 6.9x |
| Thu, 01 Dec 2022 | CN¥1.3t | CN¥175.5b | CN¥37.9b | 38.5x | 33.4x | 7.2x |
| Sat, 29 Oct 2022 | CN¥1.2t | CN¥176.6b | CN¥38.4b | 35.5x | 30.3x | 6.6x |
| Mon, 26 Sep 2022 | CN¥1.1t | CN¥174.0b | CN¥40.1b | 29.6x | 27.6x | 6.4x |
| Wed, 24 Aug 2022 | CN¥1.2t | CN¥173.0b | CN¥43.2b | 35.9x | 28.4x | 7.1x |
| Fri, 22 Jul 2022 | CN¥1.3t | CN¥168.3b | CN¥42.5b | 36.9x | 30.6x | 7.7x |
| Sun, 19 Jun 2022 | CN¥1.3t | CN¥168.1b | CN¥42.4b | 38.2x | 30.3x | 7.6x |
| Tue, 17 May 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 35.4x | 29.1x | 7.3x |
| Thu, 14 Apr 2022 | CN¥1.4t | CN¥153.2b | CN¥40.8b | 38.2x | 33.7x | 9x |
| Sat, 12 Mar 2022 | CN¥1.4t | CN¥152.2b | CN¥40.8b | 47x | 34.8x | 9.3x |
| Mon, 07 Feb 2022 | CN¥1.4t | CN¥143.8b | CN¥38.7b | 43.1x | 35x | 9.4x |
| Wed, 05 Jan 2022 | CN¥1.5t | CN¥141.8b | CN¥38.5b | 50.2x | 39.7x | 10.8x |
| Fri, 03 Dec 2021 | CN¥1.6t | CN¥141.6b | CN¥39.1b | 50.5x | 39.7x | 11x |
| Sun, 31 Oct 2021 | CN¥1.5t | CN¥137.7b | CN¥37.8b | 45.5x | 40.8x | 11.2x |
| Tue, 28 Sep 2021 | CN¥1.6t | CN¥130.3b | CN¥33.4b | 47.5x | 47.4x | 12.1x |
| Thu, 26 Aug 2021 | CN¥1.6t | CN¥130.3b | CN¥33.4b | 47.3x | 48.9x | 12.6x |
| Fri, 02 Jul 2021 | CN¥1.9t | CN¥129.8b | CN¥33.3b | 57.1x | 56.1x | 14.4x |
Price to Earnings Ratio
56.1x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 51.5x which is higher than its 3-year average PE of 39.4x.
- The 3-year average PS ratio of 7.9x is higher than the industry's current PS ratio of 5.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 20% per year over the last three years.
- Meanwhile revenues for these companies have grown 7.5% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -0.066% | |
| Healthcare | -0.038% | |
| Biotech | 1.40% | |
| Biotech | 1.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688278 Xiamen Amoytop Biotech | CN¥58.17 | 10.5% +CN¥2.3b | 38.1% | PE39.4x | |
| 688363 Bloomage BioTechnology | CN¥60.03 | 6.6% +CN¥1.8b | -35.7% | PE45.2x | |
| 301301 Yili Chuanning BiotechnologyLtd | CN¥13.84 | 5.7% +CN¥1.7b | 49.9% | PE27.6x | |
| 688192 Dizal (Jiangsu) Pharmaceutical | CN¥43.50 | 9.7% +CN¥1.6b | 16.6% | PS104.8x | |
| 688520 Sinocelltech Group | CN¥44.09 | 4.1% +CN¥774.9m | -28.6% | PS9x |
